JUMP REPORT
Avg Daily Volume: 8,576,923 Market Cap: 105.04B
Sector: Consumer Goods Short Interest: 1.16
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .59/share REV: 9,800/M
___________________________________________________________
LAST QTR: EPS: .58/share ACTUAL: .70/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .39/share REV: 9,360/M
______________________________________________________
FULL YR: EPS: 2.59/share REV: 40,150/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________
BEAT/MISS RECORD: 67% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -2.27, 6.43, 1.3
EXPECTED JUMP MOVE: 8-10
——–
*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
Not all profitable companies are built to last – some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Several popular stocks – NIKE and Target – have been beaten down over recent years, widely underperforming. Given their falls from glory, are they a buy at cheaper levels?
BEAVERTON, Ore., May 29, 2025–NIKE, Inc. (NYSE: NKE) plans to release its fourth quarter fiscal 2025 financial results on Thursday, June 26, 2025, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results.
The 33-year-veteran of the sports giant will remain through October and the company is seeking a successor.
Nike’s chief innovation officer, John Hoke, is retiring, the world’s largest sportswear company said on Thursday. Hoke, who joined Nike in 1992, has served as the company’s chief design officer before being named chief innovation officer in 2023. Earlier this month, Nike CEO Elliott Hill, who took the helm in October to lead a turnaround, had made several changes to the senior leadership team, including promoting insider Phil McCartney to be the new chief innovation, design & product officer.
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.